| Dr Leslie Pidgeon, DO | |
|
3500 W. Wheatland Road, Dallas, TX 75237 | |
| (214) 947-5400 | |
| Not Available |
| Full Name | Dr Leslie Pidgeon |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 3500 W. Wheatland Road, Dallas, Texas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255536850 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | BP10022374 (Texas) | Primary |
| Entity Name | Concord Medical Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083630610 PECOS PAC ID: 0446296818 Enrollment ID: O20050707000531 |
News Archive
Osteoarthritis is the most common form of arthritis worldwide, affecting more than 300 million people. It causes substantial pain, functional limitations, and disability in patients.
Opsens Inc. said today that its Medical Division has reached a significant milestone, successfully completing a pre-clinical animal study on the EasyWire device, designed to measure Fractional Flow Reserve in the evaluation of coronary lesions.
Scientists have discovered that a cellular enzyme helps ferry HIV genetic instructions out of the cell nucleus where they can then be translated into proteins to begin their most destructive work.
Novartis today announced new two-year results demonstrating sustained efficacy with Cosentyx (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes from the extension study of the pivotal Phase III FIXTURE and ERASURE trials.
› Verified 9 days ago
| Entity Name | National Medical Professionals Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912120874 PECOS PAC ID: 3375859408 Enrollment ID: O20150903000965 |
News Archive
Osteoarthritis is the most common form of arthritis worldwide, affecting more than 300 million people. It causes substantial pain, functional limitations, and disability in patients.
Opsens Inc. said today that its Medical Division has reached a significant milestone, successfully completing a pre-clinical animal study on the EasyWire device, designed to measure Fractional Flow Reserve in the evaluation of coronary lesions.
Scientists have discovered that a cellular enzyme helps ferry HIV genetic instructions out of the cell nucleus where they can then be translated into proteins to begin their most destructive work.
Novartis today announced new two-year results demonstrating sustained efficacy with Cosentyx (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes from the extension study of the pivotal Phase III FIXTURE and ERASURE trials.
› Verified 9 days ago
| Entity Name | Century Integrated Partners, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447615711 PECOS PAC ID: 6406151703 Enrollment ID: O20160224002152 |
News Archive
Osteoarthritis is the most common form of arthritis worldwide, affecting more than 300 million people. It causes substantial pain, functional limitations, and disability in patients.
Opsens Inc. said today that its Medical Division has reached a significant milestone, successfully completing a pre-clinical animal study on the EasyWire device, designed to measure Fractional Flow Reserve in the evaluation of coronary lesions.
Scientists have discovered that a cellular enzyme helps ferry HIV genetic instructions out of the cell nucleus where they can then be translated into proteins to begin their most destructive work.
Novartis today announced new two-year results demonstrating sustained efficacy with Cosentyx (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes from the extension study of the pivotal Phase III FIXTURE and ERASURE trials.
› Verified 9 days ago
| Entity Name | Hennacare Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174135107 PECOS PAC ID: 2961820790 Enrollment ID: O20200910003200 |
News Archive
Osteoarthritis is the most common form of arthritis worldwide, affecting more than 300 million people. It causes substantial pain, functional limitations, and disability in patients.
Opsens Inc. said today that its Medical Division has reached a significant milestone, successfully completing a pre-clinical animal study on the EasyWire device, designed to measure Fractional Flow Reserve in the evaluation of coronary lesions.
Scientists have discovered that a cellular enzyme helps ferry HIV genetic instructions out of the cell nucleus where they can then be translated into proteins to begin their most destructive work.
Novartis today announced new two-year results demonstrating sustained efficacy with Cosentyx (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes from the extension study of the pivotal Phase III FIXTURE and ERASURE trials.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Leslie Pidgeon, DO 3500 W. Wheatland Road, Dallas, TX 75237 Ph: (214) 947-5400 | Dr Leslie Pidgeon, DO 3500 W. Wheatland Road, Dallas, TX 75237 Ph: (214) 947-5400 |
News Archive
Osteoarthritis is the most common form of arthritis worldwide, affecting more than 300 million people. It causes substantial pain, functional limitations, and disability in patients.
Opsens Inc. said today that its Medical Division has reached a significant milestone, successfully completing a pre-clinical animal study on the EasyWire device, designed to measure Fractional Flow Reserve in the evaluation of coronary lesions.
Scientists have discovered that a cellular enzyme helps ferry HIV genetic instructions out of the cell nucleus where they can then be translated into proteins to begin their most destructive work.
Novartis today announced new two-year results demonstrating sustained efficacy with Cosentyx (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes from the extension study of the pivotal Phase III FIXTURE and ERASURE trials.
› Verified 9 days ago
Dr. Juan F Quiroz, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 4811a Columbia Ave, Dallas, TX 75226 Phone: 214-823-5590 Fax: 214-823-6638 | |
Dr. Michelle Dobbs, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 6333 E Mockingbird Ln, Suite 126, Dallas, TX 75214 Phone: 214-826-6005 | |
Howard J Huntzinger, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 9250 Amberton Pkwy, Dallas, TX 75243 Phone: 682-236-3656 | |
Robert J Dimeff, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8081 Walnut Hill Ln, Dallas, TX 75231 Phone: 214-750-1207 Fax: 214-739-5029 | |
Pardeep K Shori, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 7012 La Vista Dr, Dallas, TX 75214 Phone: 817-564-5761 | |
Mary Elizabeth Wilcox Smith, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2921 Fairmount St, Dallas, TX 75201 Phone: 214-742-9310 | |
Elizabeth Chapek, DO Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 6760 Abrams Rd, Suite 203, Dallas, TX 75231 Phone: 214-341-8742 |